Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Net Common Stock Issuance

Last Annual Value

1.09M

3-Year CAGR

-49%

5-Year CAGR

-62%

10-Year CAGR

101%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

CGEM · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.09M
-69.5%-66.7%N/A 
3.30M
N/AN/AN/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
5.44M
N/AN/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
0.00
N/AN/AN/A
1.05M
N/AN/AN/A
19.93M
-55.9%83.4%N/A
152.01M
371.8%1.7%N/A
46.99M
N/A41.2%2.1%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21